Good evening :)
$
₹
Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

CRVS

NASDAQ
Asset Logo

Corvus Pharmaceuticals Inc

CRVS

NASDAQ
$10.427.13% (+0.69)
$
₹
$10.427.13% (+0.69)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $889.2M the stock is ranked 2881

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.66
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.62
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 8 analysts reports

Buy
8 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+214.06%

Earnings Growth

-52.45%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.57
20.57
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 214.06% growth, versus a trailing 3-year CAGR of 92.58%.

2026
Current$10.03Baseline
Analyst Target - 1 year
Target$31.5+214.06%

All values in $

202220232024202520262027$9.24$17.71$26.18Target+214.06%
2026
Current$10.03Baseline
Analyst Target - 1 year
Target$31.5+214.06%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.51Baseline
Forecast for Dec 2026
High$-0.71-39.22%
Average$-0.78-52.45%
Low$-0.81-58.82%

All values in $

202120222023202420252026-1.06-0.89-0.57-0.93-0.51Low-58.82%Average-52.45%High-39.22%
2025
Current$-0.51Baseline
Forecast for Dec 2026
High$-0.71-39.22%
Average$-0.78-52.45%
Low$-0.81-58.82%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-10.1
-12.3
-13.6
-17.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000.08000000
Net Income-5.70-4.26-40.21-12.1115.19-7.99-10.15-12.32-13.69-17.95
Net Profit Margin----13764.77%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Corvus Pharmaceuticals Inc -3.660
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CRVS with any stock or ETF
Compare CRVS with any stock or ETF
Comparing from
CRVS
ABBV
AMGN
Loading...

Frequently asked questions

  1. Corvus Pharmaceuticals Inc (CRVS) share price today is $10.42 as of November 6, 2026 at 10:12 PM IST. The stock touched a day high of $10.50 and a day low of $9.68.

  2. Corvus Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol CRVS.

  3. Corvus Pharmaceuticals Inc's market capitalization is $889.15M as of November 6, 2026 at 10:12 PM IST.

  4. Corvus Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Corvus Pharmaceuticals Inc's price-to-book (P/B) ratio is 3.66 as of November 6, 2026.

  6. Yes, You can buy Corvus Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Corvus Pharmaceuticals Inc shares in three steps: 1. Search Corvus Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Corvus Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Corvus Pharmaceuticals Inc (CRVS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.9593 shares at the current price of $10.42.

Loading...